

JAN 14 2005

PATENT & TRADEMARKS

Substitute for form 1449A/PTO

STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

COMPLETE IF KNOWN

Application Number	10/770,138
Confirmation Number	9660
Filing Date	February 2, 2004
First Named Inventor	Paul John Rennie
Group Art Unit	1617
Examiner Name	
Attorney Docket Number	9510

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³	Number ⁴				
KC	30	DE	3431727 A1	03/13/1986	Hempel		X
KC	31	EP	0046409 A1	02/24/1982	Walliczek		
KC	32	EP	0310317 A2	04/05/1989	Bordt, et al.		
KC	33	EP	0371421 A2	06/06/1990	Sehm		
KC	34	EP	0408330 A2	01/16/1991	Masterson		
KC	35	EP	0505374 B1	04/23/1997	Deihl		
KC	36	EP	0856316 A1	08/05/1998	Sawa		
KC	37	WO	92/20352 A1	11/26/1992	Budorov, et al.		X
KC	38	WO	94/22428 A1	10/13/1994	Morrey, et al.		
KC	39	WO	99/44622 A1	09/10/1999	Ormerod, et al.		
KC	40	WO	03/086408 A1	10/23/2003	Linden, et al.		
KC	41	WO	03/092654 A1	11/13/2003	Edwards, et al.		
KC	42	WO	03/094902 A2	11/20/2003	Lin		
KC	43	WO	03/105775 A2	12/24/2003	Leonard, et al.		
EXAMINER		DATE CONSIDERED					


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [+]

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



PTO/SB08B (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 2 of 2

COMPLETE IF KNOWN

Application Number	10/770,138
Confirmation Number	9660
Filing Date	February 2, 2004
First Named Inventor	Paul John Rennie
Group Art Unit	1617
Examiner Name	
Attorney Docket Number	9510

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	CITE NO. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	44	A. C.W. LAU et al., "Editorial Overview Severe Acute Respiratory Syndrome Treatment: Present Status and Future Strategy", Current Opinion in Investigational Drugs, Vol. 4, No. 8, pp. 918 – 920 (2003).	
KC	45	GWALTNEY, JR., "Upper Respiratory Infections – The Common Cold", Principles and Practices of Infectious Diseases, 3 rd Edition, Published by Churchill Livingstone, Section B, No. 42, pp. 489 – 493, (1990).	
KC	46	DOUGLAS, et al., "Prophylactic Efficacy of Intranasal Alpha ₂ -Interferon Against Rhinovirus Infections in the Family Setting", The New England Journal of Medicine, Vol. 314, No. 2, pp. 65 – 70 (1/9/1986).	
KC	47	HIGGINS, et al., "A Study of the Efficacy of the Bradykinin Antagonist, NPC 567, in Rhinovirus Infections in Human Volunteers", Antiviral Research, Vol. 14, pp. 339 – 344, (1990).	
KC	48	FARR, et al., "A Randomized Controlled Trial of Glucocorticoid Prophylaxis against Experimental Rhinovirus Infection", The J. of Infectious Diseases, Vol. 162, pp. 1173 – 1177. (1990).	
KC	49	BARROW, et al. "The Effect of Intranasal Nedocromil Sodium on Viral Upper Respiratory Tract Infections in Human Volunteers", Clinical and Experimental Allergy, Vol. 20, pp. 45 – 51 (1990).	
KC	50	GWALTNEY, JR., "Combined Antiviral and Antimediator Treatment of Rhinovirus Colds", The J. of Infectious Diseases, Vol. 166, pp. 776 – 782 (1992).	
KC	51	POTTER et al., "Dias Rounds: Zinc Lozenges for Treatment of Common Colds", The Annals of Pharmacotherapy, Vol. 27, pp. 589 – 592 (1993).	
KC	52	ELLIOT, "Influenza Prevention and Treatment – An Update", The Pharmaceutical J., Vol. 265, pp. 446 – 451 (9/23/2000).	
KC	53	BELSHE, et al. "Genetic Basis of Resistance of Rimantadine Emerging During Treatment of Influenza Virus Infection", J. of Virology, pp. 1508 – 1512 (5/1998).	
KC	54	HAY, "The Action of Adamantanamines against influenza A viruses: Inhibition of the M2 ion Channel Protein", Virology, Vol. 3, pp. 21 – 30 (1992).	
KC	55	MONTO, et al. "Zanamivir in the prevention of Influenza among healthy adults", JAMA, Vol. 282, no. 1, pp. 31 – 35 (7/7/1999).	
KC	56	TREANOR, et al. "Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza", JAMA, Vol. 283, No. 8, pp. 1016 – 1024 (2/23/2000).	
KC	57	HUGHES, et al. "Acid Lability of Rhinovirus Type 14: Effect of pH, Time, and Temperature" Proc. Soc. Exp. Biol. Med., pp. 555 – 560 (1993).	

EXAMINER	/Kendra Carter/	DATE CONSIDERED	12/13/2006
----------	-----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JUN-02-2006 13:03

P&G-HC PATENT DIV.

RECEIVED
CENTRAL FAX CENTER 513 622 3300 P. 04/06

JUN 02 2006

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-03)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		COMPLETE IF KNOWN	
		Application Number	10/770,138
		Confirmation Number	9660
		Filing Date	February 2, 2004
		First Named Inventor	Paul John Rennie
		Group Art Unit	1617
		Examiner Name	
		Attorney Docket Number	9510

U. S. PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

HTO-SB08